Literature DB >> 12027785

Practical approaches to migraine management.

Seymour Diamond1, Richard Wenzel.   

Abstract

Migraine is a recurrent clinical syndrome characterised by combinations of neurological, gastrointestinal and autonomic manifestations. The exact pathophysiological disturbances that occur with migraine have yet to be elucidated; however, cervico-trigemino-vascular dysfunctions appear to be the primary cause. Despite advances in the understanding of the pathophysiology of migraine and new effective treatment options, migraine remains an under-diagnosed, under-treated and poorly treated health condition. Most patients will unsuccessfully attempt to treat their headaches with over-the-counter medications. Few well designed, placebo-controlled studies are available to guide physicians in medication selection. Recently published evidence-based guidelines advocate migraine-specific drugs, such as serotonin 5-HT(1B/1D) agonists (the 'triptans') and dihydroergotamine mesylate, for patients experiencing moderate to severe migraine attacks. Additional headache attack therapy options include other ergotamine derivatives, phenothiazines, nonsteroidal anti-inflammatory agents and opioids. Preventative medication therapy is indicated for patients experiencing frequent and/or refractory attacks.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12027785     DOI: 10.2165/00023210-200216060-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  174 in total

1.  Long-acting propranolol in the prophylaxis of migraine: a comparative study of two doses.

Authors:  J D Carroll; M Reidy; P A Savundra; N Cleave; J McAinsh
Journal:  Cephalalgia       Date:  1990-04       Impact factor: 6.292

2.  Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache.

Authors:  A Mauskop; M Farkkila; R Hering-Hanit; A Rapoport; J Warner
Journal:  Curr Med Res Opin       Date:  1999       Impact factor: 2.580

3.  Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group.

Authors:  A Klassen; A Elkind; M Asgharnejad; C Webster; A Laurenza
Journal:  Headache       Date:  1997 Nov-Dec       Impact factor: 5.887

4.  Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial.

Authors:  R B Lipton; W F Stewart; A M Stone; M J Láinez; J P Sawyer
Journal:  JAMA       Date:  2000 Nov 22-29       Impact factor: 56.272

5.  Dose effectiveness and safety of butorphanol in acute migraine headache.

Authors:  R M Elenbaas; C U Iacono; K J Koellner; J P Pribble; M Gratton; G Racz; R P Evens
Journal:  Pharmacotherapy       Date:  1991       Impact factor: 4.705

6.  Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group.

Authors:  W H Visser; M D Ferrari; E M Bayliss; S Ludlow; A J Pilgrim
Journal:  Cephalalgia       Date:  1992-10       Impact factor: 6.292

7.  A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group.

Authors: 
Journal:  Eur Neurol       Date:  1991       Impact factor: 1.710

8.  Flurbiprofen in the prophylaxis of migraine.

Authors:  G D Solomon; R S Kunkel
Journal:  Cleve Clin J Med       Date:  1993 Jan-Feb       Impact factor: 2.321

9.  A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group.

Authors:  M S Kramer; D Matzura-Wolfe; A Polis; A Getson; P G Amaraneni; M P Solbach; W McHugh; J Feighner; S Silberstein; S A Reines
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

10.  A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice.

Authors:  M B Russell; O E Holm-Thomsen; M Rishøj Nielsen; A Cleal; A J Pilgrim; J Olesen
Journal:  Cephalalgia       Date:  1994-08       Impact factor: 6.292

View more
  3 in total

Review 1.  Eletriptan: a review of its use in the acute treatment of migraine.

Authors:  Paul L McCormack; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Comparison between Intravenous Sodium Valproate and Subcutaneous Sumatriptan for Treatment of Acute Migraine Attacks; Double-Blind Randomized Clinical Trial.

Authors:  Abolghasem Rahimdel; Ali Mellat; Ahmad Zeinali; Elahe Jafari; Parisa Ayatollahi
Journal:  Iran J Med Sci       Date:  2014-03

Review 3.  [Formalized consensus: clinical practice recommendations for the management of the migraine in African adult patients].

Authors:  Mahmoud Ait Kaci Ahmed; Monia Haddad; Beugré Kouassi; Hamid Ouhabi; Alain Serrie
Journal:  Pan Afr Med J       Date:  2016-05-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.